Although the novel therapy such as programmed cell death-1 (PD-1) immune checkpoint inhibitor has made a great breakthrough, it has come to a dilemma as pancreatic cancer cells are endowed with the ability to escape or defend the therapy by the intangible, subtle and dynamic TME [145]. This evidence concerns the gene PDCD1 and familial pancreatic carcinoma.